Daily Roundup

AYA.ASX XRG.ASX NST.ASX EYE.ASX CSL.ASX

Artrya Ltd is making solid headway with its Salix® AI platform, a tool designed to assess coronary artery disease. The company's U.S. customer base is expanding, with Northeast Georgia Health System set to go live next month. Meanwhile, validation work on Salix® Coronary Flow is nearly complete, putting an FDA submission within reach. The company has also kicked off the SAPPHIRE Study and is advancing its Clinical Advisory Board formation to strengthen its clinical strategy stateside. With a pro forma cash position of $74.0 million, Artrya appears well-positioned to accelerate commercialization with an increasingly repeatable deployment model.

XReality Group Limited is firing on all cylinders. The company's Q4 FY26 cash receipts jumped 46% year-over-year to $6.9 million, while net operating cash flow for the full year hit $5.8 million—an impressive 88% increase. The customer base has grown to 118 worldwide, up 76% year-over-year, with 108 of those in the U.S. Annual Recurring Revenue reached $8.0 million, up 69% year-over-year. The company also landed its first European contract with the Swedish Armed Forces, worth approximately $0.45 million, and wrapped up a $5.6 million U.S. Department of Defense project right on schedule and budget.

Northern Star Resources Ltd delivered a solid quarter with 433,482 ounces of gold sold at an all-in sustaining cost of A$2,651 per ounce. The company's net mine cash flow came to A$1,179 million across its Kalgoorlie, Yandal, and Pogo production centers. The standout development is the KCGM Mill Expansion Project, which has entered its commissioning phase with Stage 1 ramping up expected in the first half of FY27. The company also announced a leadership change, with Suresh Vadnagra taking over as Managing Director and CEO effective October 5, 2026. Northern Star is guiding for FY26 cash earnings of A$2,860–2,950 million, with full FY27 guidance and a final investment decision on the Hemi Project targeted for late FY27.

Nova Eye Medical Ltd is hitting its stride with total sales reaching US$23.7 million for FY26, a 26% jump year-over-year. Excluding China, sales climbed 29% to US$22.7 million. The real milestone here is achieving positive EBITDA of US$0.14 million in the second half of FY26, ahead of expectations. Cash outflow from operations has tightened to just A$0.2 million for the quarter. Looking ahead, the company expects FY27 sales excluding China to land between US$26 million and US$31 million, with positive EBITDA anticipated to continue.

CSL Limited is investing in its future with plans to launch clinical trials for its Horizon 2 plasma manufacturing process in mid-2027 at its Broadmeadows facility. The new technology is designed to significantly boost immunoglobulin production from the same plasma base. CSL has already been working with the FDA and EMA to gather the clinical evidence needed for regulatory approval, signaling a methodical approach to bringing this innovation to market.